Mr. Dr. Pfister's management career includes 19 years at Sandoz and then Novartis Pharmaceuticals in France, Switzerland and in the US, where he has occupied positions of growing responsibility in a range of therapeutic fields, including the inflammatory and cardiometabolic disease areas.
Before joining NicOx in July 2007, he was Vice President, Global Therapeutic Area Head for Respiratory & Dermatology, Clinical Development & Medical Affairs where he was responsible for managing a large team across Europe and the US.

He has successfully participated in the development and subsequent launch and marketing of several brands, including Lescol® (fluvastatin) for hypercholesterolemia and Foradil® and Xolair® for the treatment of asthma. Dr. Pfister was also actively involved in the optimization of the late stage development plans for Starlix® for the treatment of type 2 diabetes and Prexige®, a COX-2 Inhibitor for the treatment of osteoarthritis. He led the medical support teams for the launch of Elidel® for atopic dermatitis, Zelnorm® for Irritable Bowel Syndrome (USA) and at an international level for Myfortic® and Certican® in the field of organ transplantation.

Pascal Pfister is a Medical Doctor, who graduated from the Necker School of Medicine of the University René Descartes in Paris and he also holds a diploma in pharmaceutical medicine. Prior to joining the Pharmaceutical Industry, Dr. Pfister held a post-doctoral position where he studied drugs that affect lipid metabolism at the Clinical Research Institute of Montreal, Canada.